Host: John Anderson, MD Host: John Buse, MD, PhD Host: Carol Wysham, MD The wintertime presents new challenges for patients with chronic diseases, specifically diabetes. But with the spread of COVID-19, how can we help keep our patients safe all winter long? Tune in to hear our Diabetes Discourse hosts Drs. Carol Wysham, John Buse, and John Anderson discuss strategies to effectively manage patients with diabetes during these winter months. Published December X, 2020

Focus on Diabetes

Managing Diabetes & COVID-19 in the Wintertime

Host: Linda Bernstein, Pharm.D. In this episode of The Drug Report, pharmacist Dr. Linda Bernstein highlights some diabetes medications that have achieved or are pending approval for new indications pertaining to cardiovascular disease risk reduction.

A Look at Diabetes Drugs That Reduce the Risk of Cardiovascular Disease

Host: Linda Bernstein, Pharm.D. On this episode of The Drug Report, pharmacist Dr. Linda Bernstein focuses on a recent CVS Health announcement of their new plan that allows employers and health plan sponsors to work within a formulary and plan design to offer all types of diabetes medications—including insulin—at zero-dollar out of pocket for their members without raising costs for the plan sponsor or increasing premiums or deductibles for all plan members.

A New Health Plan to Eliminate Diabetes Patients’ Out-of-Pocket Costs

Host: Janine Austin Clayton, MD Guest: A. Paul Chous, MA, OD, FAAO, CDE Guest: Anne Peters, MD When it comes to protecting the vision of our patients with diabetes, the importance of taking assertive action cannot be ignored. But another key aspect that can unfortunately be easy to overlook is care collaboration. Featuring Dr. Janine Clayton, Dr. A. Paul Chous, and Dr. Anne Peters, this discussion will focus on how providers can work together to optimize patients’ eye health and minimize their risk of vision loss from diabetic retinopathy and diabetic macular edema. Vision loss caused by diabetic retinopathy can have a significant impact on a patient's quality of life. This activity emphasizes more assertive action in clinical practice for patient with diabetes. The acronym ASSERT-D is a reminder to Assess and Screen for Eye health and Refer or Treat patients with Diabetes.

In Plain Sight: Evaluating All Patients with Diabetes for Diabetic Retinopathy

Guest: Michael H. Davidson, MD Tune in as Dr. Michael Davidson, a preventive cardiologist from the University of Chicago Pritzker School of Medicine, outlines what a diabetes cardiovascular outcomes trial (CVOT) is, the differences between CVOTs and glycemic efficacy trials, and how these studies are designed and assessed. US19HCP00067 July 2019

Diabetes Cardiovascular Outcomes Trials: What You Need to Know

Host: Jennifer Caudle, DO Guest: Christie Ballantyne, MD With the number of patients with both type 2 diabetes and established cardiovascular disease on the rise, a personalized patient approach to treating these two conditions is now more important than ever. Joining Dr. Jennifer Caudle to discuss the role of the cardiologist in managing patients with type 2 diabetes is Dr. Christie Ballantyne. US18VZ00285 January 2019

Role of the Cardiologist in T2D Management

Host: Jennifer Caudle, DO Guest: Mikhail Kosiborod, MD Guest: Christie Ballantyne, MD Since type 2 diabetes and cardiovascular disease often go hand in hand, having a care collaboration plan in place is essential in managing these conditions. Here to discuss both the challenges and opportunities that arise when collaborating patient care are cardiologists Dr. Mikhail Kosiborod and Dr. Christie Ballantyne. US18VZ00286 January 2019

Care Collaboration: Patients with Type 2 Diabetes & Established Cardiovascular Disease – The Cardiologists' Perspective

Host: Jennifer Caudle, DO Guest: Mikhail Kosiborod, MD Type 2 diabetes and established cardiovascular disease continues to impact patients and more focus is now set on addressing these patients’ unmet needs. Joining Dr. Jennifer Caudle is cardiologist Dr. Mikhail Kosiborod, who discusses a more reflexive approach to disease management that aims to close this gap in care. US18VZ00284 January 2019

Unmet Clinical Needs for Patients with T2D & Established CVD

Host: Barnett Mennen, MD Guest: Sarah Hallberg, MD Carbohydrates are our main source of energy and provide important nutrients for good health. However, they are also the main culprit behind elevated blood sugar and are problematic for diabetic patients trying to control their blood sugar levels. Host Dr. Barry Mennen sits down with Dr. Sarah Hallberg to talk about carbohydrate restriction as a key to successful weight loss programs. She prescribes that adherence to a low-carb, high-fat diet is vital to patients for controlling their diabetes, with the possibility of being able to come off medications over time. Dr. Sarah Hallberg is the Medical Director at Virta Health and Founder of the Indiana University-Arnett Health Medical Weight Loss Program in Lafayette, Indiana. 

Is a Low-Carb, High-Fat Diet the Key to Diabetic Management?

Based on new data from two large clinical trials, the FDA concluded that the type 2 diabetes medicine canagliflozin (brand names Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations. The FDA is requiring new warnings, including their most prominent Boxed Warning, be added to the canagliflozin drug labels to describe this risk. Amputations of the toe and middle of the foot were the most common; however, amputations involving the leg, below and above the knee, also occurred. Some patients had more than one amputation, some involving both limbs. Report side effects involving canagliflozin and other medicines to the FDA MedWatch program at fda.gov/medwatch. A link to the full communication detailing specific information for health care professionals and the complete Data Summary can be found at fda.gov/DrugSafetyCommunications. If you have drug questions, contact the FDA at druginfo@fda.hhs.gov. Released 5/16/2017

FDA Confirms Leg and Foot Amputation Risk with Diabetes Medicine Canagliflozin

Host: Brian P. McDonough, MD, FAAFP Diabulimia, defined as the manipulation of insulin treatments by Type 1 diabetic patients in order to lose weight, is a rising problem among teens and young adults in the U.S, particularly young women. Joining Dr. Brian McDonough to discuss this dual diagnosis phenomenon of diabetes and eating disorders, ways in which they exacerbate other disease processes, the long term consequences, and management priorities for phycisians is author and registered dietitian Susan Weiner. Susan is a recipient of the AADE Diabetes Educator of the Year award and has devoted much of her writing and clinical expertise to addressing diabulimia in at-risk patients.

The Rising Diabulimia Epidemic: Safeguarding Diabetic Patients with Eating Disorders

[Read the Article] Despite targeted efforts to reduce obesity through diet and exercise, these rates continue to rise. A new study from Ontario, Canada found that obesity and diabetes rates were lower in more walkable neighborhoods compared to less walkable neighborhoods, where they saw an increase in these rates.Researchers from St. Michael's Hospital in Toronto studied almost 9,000 neighborhoods in Southern Ontario looking at walkability scores, along with government health data and survey results during a twelve-year period. They examined whether neighborhoods that were more walkable experienced a slower increase in obesity and diabetes compared to less walkable neighborhoods. [Watch more videos of The JAMA Report] 

Rates of Obesity and Diabetes Lower in More Walkable Neighborhoods

Host: Jennifer Caudle, DO Host Jennifer Caudel, DO welcomes Jay Shubrook, DO, Director of Clinical Research and Diabetes Services at Touro University-California College of Osteopathic Medicine. Recorded on site at the American Osteopathic Association's annual medical education conference, Dr. Shubrook discusses a pilot study in which newly diagnosed type 2 diabetes patients were treated with early insulin rather than lifestyle changes and oral therapies alone. The results suggested not only good safety profiles, but also better long-term outcomes for patients.

Diabetes Research Suggests Better Long Term Outcomes with Early Insulin

[Read the Article] Proliferative diabetic retinopathy (PDR) is a leading cause of vision loss in patients with diabetes, resulting in up to 24,000 cases of blindness each year in the United States. Laser therapy has been the most common treatment used to help reduce severe vision loss, but the procedure has many side effects including permanent loss of peripheral vision and swelling of the retina.A group of researchers from across the US tested an alternative treatment using an injectable medication called ranibizumab, to see if it would be as effective as the laser therapy. They studied more than 300 patients with PDR, assigning them to either receive standard laser therapy or an injection into the eye. In total, they treated close to 400 eyes.Outcomes, especially loss of vision, were compared at two years. Over the two year period, researchers found that patients receiving the injections of medication had fewer side effects and did somewhat better in terms of vision loss than those who received laser therapy. [Watch more videos of The JAMA Report]

Injectable Medication as an Alternative Treatment for Diabetic Eye Disease

Host: John J. Russell, MD Guest: Candis Morello, PharmD, CDE Candis M Morello, Professor of Clinical Pharmacy at UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, joins Dr. John Russell to talk about team-based care integrations of certified diabetes educators to help empower diabetes patients and improve long-term outcomes. Diabetes Discourse, a non-certified educational series, is brought to you by AstraZeneca, pushing the boundaries of science to create life-changing medicines for people with diabetes. Content of this diabetes education is produced and solely controlled by ReachMD. This series is intended for healthcare professionals only. Brought to you by 

The Role of the Certified Diabetes Educator: A Team Effort

ReachMD takes an in-depth look at diabetes, a disease identified in nearly 1 in 10 Americans, which upsets the lives of millions more. Even more disturbing, the rates of new cases of diagnosed diabetes have risen almost twofold during the past decade. Nutrition, exercise and genetics are all factors in how the disease affects children, adults and the elderly, but that's only the beginning. How are surgical options changing the way we think about the disease? How close are we to a cure for Type 1 diabetes? Are there treatment lessons we can take from community-based initiatives abroad? Tune in to gain insights for your practice.

hubhopper

Focus on Diabetes

hubhopper